BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Debt Repayment
Cash used to repay borrowings during the period.
BioAge Labs, Inc.NASDAQ: BIOA
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment grows in line with its trailing trend
Q1 FY2026 debt repayment of $1.5M (cash outflow) rose 0.0% year over year, in line with the +0.0% change in trailing-twelve-month debt repayment. Sequentially, it rose 0.0% from the prior quarter.
Context
- Debt repayment amounted to 66.7% of revenue in FY2025.
- Debt repayment increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of +0.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (6M) USD
- Year-over-year change
- +0.0%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6M) | +0.0% |
| FY2024 | 2024-12-31 | (6M) | -117.1% |
| FY2023 | 2023-12-31 | 35M | +1300.0% |
| FY2022 | 2022-12-31 | 2.5M | — |
Debt Repayment vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.0% is the 5th highest of 6, against a peer median of +156.7%.
- Debt repayment amounts to 58.2% of revenue for BIOA, versus a peer median of 4.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.07M USD | +44233.3% | — | 1838.9% | |
| LTM Mar 2026 | CA$13.52M CAD | -93.9% | — | 4.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $6M USD | +0.0% | — | 58.2% |
| LTM Mar 2026 | $5.13M USD | — | -30.6% | 3.8% | |
| LTM Mar 2026 | CA$4.24M CAD | +426.3% | — | 1.4% | |
| LTM Mar 2026 | $3.72M USD | +156.7% | — | — | |
| LTM Mar 2026 | $2.87M USD | — | — | 7.4% | |
| LTM Mar 2026 | $2.15M USD | +93.3% | -52.2% | 5.1% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding BIOA) | — | +156.7% | -41.4% | 4.7% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.